Literature DB >> 34767157

Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta.

Ali Sarbazi-Golezari1, Hashem Haghdoost-Yazdi2.   

Abstract

Human studies indicate that Parkinson's disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  6-OHDA; DAergic neuronal death; FFA; Glucose; IL-1β; Parkinson’s disease; Substantia nigra

Mesh:

Substances:

Year:  2021        PMID: 34767157     DOI: 10.1007/s11011-021-00868-4

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  28 in total

1.  Some biochemical aspects of extrapyramidal diseases.

Authors:  A BARBEAU; T L SOURKES
Journal:  Rev Can Biol       Date:  1961-06

Review 2.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

3.  Influence of tail versus cardiac sampling on blood glucose and lipid profiles in mice.

Authors:  Yih Kai Chan; Paul F Davis; Sally D Poppitt; Xueying Sun; Nicholas S Greenhill; Rita Krishnamurthi; Aneta Przepiorski; Anne-Thea McGill; Geoffrey W Krissansen
Journal:  Lab Anim       Date:  2012-03-07       Impact factor: 2.471

4.  Selenium and Other Trace Elements in the Etiology of Parkinson's Disease: A Systematic Review and Meta-Analysis of Case-Control Studies.

Authors:  Giorgia Adani; Tommaso Filippini; Bernhard Michalke; Marco Vinceti
Journal:  Neuroepidemiology       Date:  2019-08-27       Impact factor: 3.282

5.  Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.

Authors:  Eduardo De Pablo-Fernandez; Carmen Tur; Tamas Revesz; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

6.  Intracerebral injection of low amounts of norharman induces moderate Parkinsonism-like behavioral symptoms in rat.

Authors:  Mohammad Hossein Esmaeili; Mohadeseh Movahedi; Ayda Faraji; Hashem Haghdoost-Yazdi
Journal:  Neurotoxicol Teratol       Date:  2012-07-09       Impact factor: 3.763

7.  Neuroendocrine, sympathetic and metabolic responses induced by interleukin-1.

Authors:  F Berkenbosch; D E de Goeij; A D Rey; H O Besedovsky
Journal:  Neuroendocrinology       Date:  1989-11       Impact factor: 4.914

8.  Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.

Authors:  S Crotty; P Fitzgerald; E Tuohy; D M Harris; A Fisher; A Mandel; A E Bolton; A M Sullivan; Y Nolan
Journal:  Eur J Neurosci       Date:  2008-01-11       Impact factor: 3.386

9.  Deep brain stimulation of the subthalamic nucleus regulates postabsorptive glucose metabolism in patients with Parkinson's disease.

Authors:  Marie Batisse-Lignier; Isabelle Rieu; Christelle Guillet; Estelle Pujos; Béatrice Morio; Jean-Jacques Lemaire; Franck Durif; Yves Boirie
Journal:  J Clin Endocrinol Metab       Date:  2013-04-30       Impact factor: 5.958

10.  Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.

Authors:  B C Bowen; R E Block; J Sanchez-Ramos; P M Pattany; D A Lampman; J B Murdoch; R M Quencer
Journal:  AJNR Am J Neuroradiol       Date:  1995-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.